Street Should Focus on Upside, Not Downside with AMAG Pharmaceuticals (AMAG), Summer Street Says
Tweet Send to a Friend
Summer Street analyst Carol Werther reiterated her Buy rating and $43 price target on AMAG Pharmaceuticals (NASDAQ: AMAG) Tuesday, calling ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
